Join the stem cell registry – Berea Mail

Nicolene Moonsamy. Sheena Dhunlal and Stephanie Berry encourage people to attend the blood stem cell donor drive.

THE number of patients diagnosed with blood diseases is on the rise, with 75 per cent of those diagnosed under the age of 25 years.

For most of these patients, a blood stem cell transplant is their only hope of cure.

Lenmed Ethekwini Hospital and Heart Centre is partnering with The Sunflower Fund to host a blood stem cell donor drive on 27 November at 9.30am to recruit well informed and committed donors onto The Sunflower Fund Registry, The drive will take place in the auditorium on the fourth floor until 3pm.

Leukaemia, aplastic anaemia and immune deficiencies are among the few blood conditions that we treat in our practise and can be managed with a blood stem cell transplant. Stem cells make up the component that your immune system needs to function. During the transplant your body is rescued with an infusion of healthy blood stem cells, explained Dr Keshnie Moodley, treating specialist paediatrician and haematologist at KIDZCAN based at Lenmed Ethekwini Hospital and Heart Centre.

ALSO READ: Girls celebrate with The Sunflower Fund

The chances of finding this match is 1:100 000 and the best chance of a match is within your same ethnic background. There is only a 25 per cent chance that a sibling will be a match. The remaining 75 per cent chance depends on an unrelated matching donor being found. Patients of colour and mixed ethnicity around the world are at a disadvantage due to the under-representation of Black, Coloured, Indian and Asian donors in the global donor pool.

As such The Sunflower Fund proactively creates awareness and education about blood diseases as well as the process involved in becoming a blood stem cell donor. We remain a registry of donors that is representative of the people groups in our rainbow nation, who are willing to help anyone for whom they might be a match, said Stephanie Berry from The Sunflower Fund.

To attend the drive on 27 November, contact Xolani Hlongwane on 079 261 2664 or email: [emailprotected]

To become a blood stem cell donor, visit: http://www.sunflowerfund.org.

Do you want to receive news alerts viaTelegram? Send us a message (not an sms) with your name and surname to 060 532 5535.

You can also join the conversation onFacebook,TwitterandInstagram.

PLEASE NOTE: If you have signed up for our news alerts you need to save the Berea Mail Telegramnumber as a contact to your phone, otherwise you will not receive our alerts

Heres where you candownload Telegram onAndroidorApple.

Read more:
Join the stem cell registry - Berea Mail

Give someone a chance to live by joining the stem cell registry | Daily News – Independent Online

Durban - Every year individuals around the world are diagnosed with leukaemia and other life-threatening blood diseases.

For many, their only hope of a cure is a life-saving blood stem cell transplant. This is why the Sunflower Fund will be embarking on a blood stem cell donor drive which will be held on Tuesday to recruit donors onto their registry.

At least 75% of stem cell patients are under the age of 25 years, this is according to The Sunflower Fund - a scary fact and anyone is at risk of being diagnosed with a blood disease.

The Sunflower Fund spokesperson Xolani Hlongwane says that interested donors need to be between 18-45 and willing to help anyone.

Donors also need to weigh the constant weight of 50 and above, no chronic illnesses, no heart, brain or back surgery., he said.

See the rest here:
Give someone a chance to live by joining the stem cell registry | Daily News - Independent Online

Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief – PR Web

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says.

MILWAUKEE (PRWEB) November 25, 2019

The American Society of Gene & Cell Therapy (ASGCT) announced today the appointment of Roland W. Herzog, Ph.D. and Gerhard Bauer as editors-in-chief of the Societys field-leading journals, Molecular Therapy and Molecular TherapyMethods & Clinical Development, respectively. Both editors will begin their positions effective January 1, 2020.

Herzog, currently the editor-in-chief of Molecular TherapyMethods & Clinical Development, will assume the same role for a five-year term at Molecular Therapy from Seppo Yl-Herttuala, M.D., Ph.D. at the conclusion of Yl-Herttualas term. Herzog is also a professor of pediatrics, Riley Children's Foundation Professor of Immunology, and director of the gene and cell therapy program at Indiana University.

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says. My vision has continued and even further strengthened close coordination and collaboration between the journal editors and partnership with Cell Press and ASGCT.

Bauer replaces Herzog at the helm of Molecular TherapyMethods & Clinical Development after serving as an associate editor of the same journal for more than four years. Bauer is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures.

Over the years that I have been looking at manuscripts submitted to the journal, I have always loved the articles dealing with translational research, getting the products ready for clinical applications, improving their utility and solving problems in the manufacturing of these products, Bauer says. Now, at a time where we have clinical efficacy and also commercially approved cell and gene therapy products that save lives, it is even more important to strengthen the translational research field.

ASGCTs official journal, Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2018 impact factor is 8.402.

The aim of Molecular TherapyMethods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular TherapyMethods & Clinical Development's 2018 impact factor is 4.875.

In addition to Molecular Therapy and Molecular Therapy Methods & Clinical Development, ASGCT also owns and operates two other sibling journals, Molecular TherapyNucleic Acids (2018 impact factor 5.919) and Molecular TherapyOncolytics (2018 impact factor 5.710).

About ASGCTThe American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Share article on social media or email:

Read more here:
Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief - PR Web

Health: Botanix buddy set to benefit after DEA admits their synthetic CBD is probably ok – Stockhead

Following last months disastrous news that a cannabidiol (CBD) acne trial failed, Botanix (ASX:BOT) may win back doubters after convincing the DEA to de-schedule synthetic CBD.

The Drug Enforcement Agency (DEA) has removed the synthetic CBD made by Georgia-based Purisys from its druge schedule, and told the two companies on Friday it would no longer be scheduled as a controlled substance at all, because it could prove it effectively contains no THC.

Before now companies using synthetic or natural CBD needed licences from the DEA for all aspects of logistics and use, and cross-border transport was tightly controlled.

Stockhead understands this change is only for Purisys and is not an industry-wide shift in position from the DEA.

The company says the change will greatly reduce its costs.

The US drug law enforcer moved in late 2018 to re-schedule CBD generally from category 1 (in with cocaine and heroin) to category 5, meaning it considers the substance to have some medical benefit but is open to abuse.

Botanix signed with Purisys in October to supply all of the synthetic CBD it needs.

Also in October, Botanix said its acne trial failed: the 368 patient trial of BTX 1503 only worked for 40 per cent of cases, which isnt better than current non-CBD drugs on the market.

To be commercialised, drugs have to be better, not just the same.

Kazia Therapeutics (ASX:KZA) may be able to give glioblastoma (brain cancer) sufferers three more months of life with its drug, but cant be completely sure yet because thats based on data from the first eight patients with viable data, in a 29-patient phase two clinical trial. They do not yet have an overall survival rate.

Cynata (ASX:CYN) has applied for permission to start a phase two trial on critical limb ischaemia, a disease that involves the narrowing of arteries in the limbs. It generally results in amputations and is a risk factor for heart attacks. The company wants to test its Cymerus mesenchymel stem cell treatment on it.

Go here to read the rest:
Health: Botanix buddy set to benefit after DEA admits their synthetic CBD is probably ok - Stockhead

Breakthrough Discovery In Plants DNA May Lead To Slowing Aging Process In Humans – CBS Pittsburgh

(CNN) Science has identified in the plant kingdom the missing link of cellular immortality between human and single-celled animals,according to a new study led by scientists from Arizona State University and Texas A&M University.

This is the first time that we have identified the detailed structure of the telomerase component from plants, said co-author Dr. Julian Chen, a professor of biochemistry at Arizona State University. The study was published Monday in the Proceedings of the National Academy of Sciences journal.

Telomerase is the enzyme that creates the DNA of telomeres, the compound structures located at the tips of our chromosomes. Telomeres protect our cells from aging as they multiply.

So in terms of fundamental research, this is a really big breakthrough because now, finally, we have a way to study telomerase in plants and to understand how different or similar they are from animals, Chen said.

READ: Two Kids Who Died After Minivan Crashed Into Canal Identified

Could the discovery possibly lead to humans one day living as long as the fabled Methuselah tree, a bristlecone pine species that can live over 5,000 years? Maybe one day.

This is really basic research. The application to humans is really a long way away, Chen said.

In the meantime, however, experts likeUniversity of California at San Franciscos Elizabeth Blackburnare bullish. Blackburn won the2009 Nobel Prize in Physiology or Medicine along withJohns Hopkins Carol GreiderandHarvards Jack Szostak for their discoveries on telomeres and telomerase.

Excitingly, this paper reports how plants fill in the missing links of telomerase RNAs eventful evolutionary history from our simplest forebears, Blackburn said. This fundamental new understanding may pave the way to new routes to optimizing telomere maintenance for human health.

Think of telomeres as the plastic caps on the ends of your shoelaces. High levels of telomerase keep those telomeres long, thus allowing them to continue to protect our cells from damage as they divide.

Most of the cells in our body have very low levels of telomerase, and thus age as they divide (picture the shoelace tips wearing away until they are gone). Aging cells equal an aging body, with cells no longer functioning normally.

However, when the cells ends are protected by telomeres, only a piece of the telomere, or cap, is lost as the cell divides,and the important DNA is left undamaged. Considering a typical cell divides about 50 to 70 times, having no protective cap could lead to chromosome instability or cells that stop dividing.

In humans, for example, egg, sperm and stem cell chromosomes contain high levels of telomerase, and so can continue to divide over and over and avoid rapid aging.

Yet even telomeres do not have eternal life. Each time a cell replicates, about 20 base pairs are lost from the telomere, or shoelace cap. We can lose even more 50 to 100 base pairs per cell division when our bodies are in oxidative stress.

We put our bodies into oxidative stress by smoking, eating a poor diet, stress and other harmful lifestyle behaviors. Between normal wear and tear and the oxidative stress of our lifestyles, even long telomeres are worn away.

But if science could harness the secret of the telomerase enzyme, its possible that we could prolong the life of telomeres, slowing the aging process.

We might be able to reversediseases in which telomeres are shortened, such as pulmonary fibrosis.

And heres another key benefit to unraveling this mystery: Cancer cells contain high levels of telomerase, allowing them to continue replicating themselves until they form tumors.

Switching off telomerase activity in cancer cells would shorten their telomeres, whittling them down to a nub called a critical length, which then triggers programmed cell death.

The ultimate goal: stopping cancer cold.

When Blackburn, Greider and Szostak won the Nobel Prize in 2009, it was for their groundbreaking discoveries on telomeres and telomerase. They extracted telomere DNA from a single-celled organism in pond scum, showed how it protected chromosomes in yeast, and identified and named the enzyme telomerase that builds the DNA of telomeres and extends their lives.

Since then, telomerases have been found to exist almost universally across species, but in complicated ways.

This enzyme action is similar from the simplest organisms to humans, Blackburn said. Yet, the telomerase RNA part of telomerase has long presented a mystery because it is surprisingly different between different evolutionary branches of life.

Each species has unique elements to their telomere RNA, and not all appear to protect against aging. For example, some species with longer telomeres have shorter life spans than those with shorter telomeres.

Scientists continue to explore the role of telomeres and the enzyme telomerase in aging, and now believe that they may only be one part of the aging process, at least in animals.

If cells have telomerase, they will live longer, but these cells are just part of your body, Chen said. Whether it can delay the entire individuals aging or increase their life span, thats a different story.

Now science has an entirely new kingdom of telomerase to dissect: Plantae, consisting of more than 2,500 species.

Maybe telomerase activity is different in plants than in animals, Chen said. We know that some of the core is similar, but you might have some additional features that plants acquire to be plant-specific.

Were hoping to learn something from their regulation, mechanisms or structures that can apply to human telomerase, Chen said. So in terms of basic research, this is really exciting because its a brand new kingdom that we can explore as to how telomeres do their jobs in plants.

The-CNN-Wire & 2019 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Read more here:
Breakthrough Discovery In Plants DNA May Lead To Slowing Aging Process In Humans - CBS Pittsburgh

Missing Link To Longevity Discovered In The Plant Kingdom – Texas A&M University

lead researcher Dorothy Shippen, Ph.D., (left), graduate student Jiarui Song, first author (center) and postdoctoral fellow Claudia Castillo-Gonzlez, second author (right).

Texas A&M AgriLife

A breakthrough discovery by Texas A&M University and Arizona State University professors could provide a key component in understanding the human aging process and even aid in the battle against cancer.

Dorothy Shippen, Ph.D., is a University Distinguished Professor and Regents Fellow in Texas A&MsDepartment of Biochemistry and Biophysicsand withTexas A&M AgriLife Research, College Station.

Shippen co-led a study with Julian Chen, Ph.D., professor of biochemistry, Arizona State Universitys School of Molecular Sciences. First author, Jiarui Song, is a graduate student with Shippen.

Their study, The conserved structure of plant telomerase RNA provides the missing link for an evolutionary pathway from ciliates to humans, is being published in the Proceedings of the National Academy of Sciences.

Our discovery of this key component of the telomerase enzyme in the plant kingdom provides an evolutionary bridge, and a novel path forward, for understanding how humans keep their DNA safe and enable cells to divide indefinitely, Shippen said.

Moreover, since plants often evolve interesting solutions to fundamental biological problems, some of the lessons we learn from plant telomerases may provide new ways for addressing stem cell disease and cancer.

We found a core component of the telomerase enzyme that had been missing all these years, Shippen said. And by finding this component in plants, we not only learn new lessons about how telomerase evolved, but we also open the door to learn new things about the human enzyme.

Back in 2001, Shippen published a paper outlining the discovery of the catalytic subunit of the telomerase enzyme from plants. The catalytic component is one of two absolutely critical parts of the enzyme, and it is now very well understood.

However, the second component, the RNA subunit, that provides the enzyme with information about what to do with chromosome ends, was missing.

Our new discovery is the RNA subunit of telomerase from the plant kingdom. In the plant telomerase RNA, we can now see the signatures for the human telomerase and telomerase from simple organisms like bakers yeast and the microbes in pond scum.

The missing piece always was this subunit. Now that we have found the correct one, its opened up a lot of interesting insights.

Plants have different, innovative solutions to so many biological challenges, and insight into these may provide important clues on how human telomerase is regulated, she said.

We can study the telomerase enzyme more deeply and see so much more now, and it can help us understand how the human enzyme is going to work. It really is this missing middle ground.

In the 1930s, Barbara McClintockwas studying the behavior of chromosomes in maize and was one of the first scientists to appreciate the importance of telomeres.The Shippen Labin the 1990s followed up on the pioneering work of McClintock in model plant systems and discovered the telomerase enzyme, which is required for maintaining these structures on the ends of chromosomes.

Shippens longtime studies on telomerase, which play an essential role in chromosome stability and cell proliferation capacity, has led her to be considered the worlds expert in plant telomere research.

The telomere is like a biological clock. There is a certain amount of telomeric DNA at the end of chromosomes. As cells divide, they lose part of this DNA.

She has likened telomeres to the plastic tip on the end of a shoelace they form a protective seal on the ends of chromosomes in plants and animals. Like the plastic tip that wears out, allowing the shoelace to fray and become hard to use, so does the telomere break down in most cells in the human body over time.

The telomerase enzyme is capable of replenishing the lost DNA at chromosome ends and it is available in cells that are immortal, Shippen said. Its active in the stem cells, but not active in other places of the body normally.

Theres a whole connection between immortality and telomerase that needs to be studied.

Why is telomerase only active in stem cells, turned off in other cells and why does it get reactivated in cancer cells? Shippen said. Weve learned a lot about the human telomerase from pond scum, but plants can provide still more clues because their growth and development is so plastic. If you cut a flower from a plant growing in the garden, it will grow another flower. But if you cut off the tip of your finger, you wont be growing a new one.

Its a big mystery.

But Shippen said the plant telomerase is still very similar to the human telomerase.

It is remarkable that even in plants, telomerase is active only in cells that need to divide many times.

She expects that what is learned in the plant system will ultimately be translatable and have significant impact in human medicine.

Continue reading here:
Missing Link To Longevity Discovered In The Plant Kingdom - Texas A&M University

Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,…

In the forecast period, the global stem cell therapy market is expected to generate revenue about 978 million USD in 2027, growing at a CAGR of 20% by 2019-2027.

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem Cell Therapy Market are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells.

Report Consultant has added a new report to its database that qualifies an expressive and professional look into this market. The report is titled a Global stem cell therapy Market. Thus, the report scrutinizes the present-day environment of the market in order to generate a comprehensive understanding of the future plans of the market. Porters five and SWOT analysis have been utilized to scrutinize the Global stem cell therapy Market.

Grab Eye-Popping Black Friday Deals on this Report @

Top Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, and Takeda (TiGenix)

The report provides a brief timeline for each segment of the stem cell therapy market. Key drivers and restraints impacting the market segments are also demonstrated precisely. It also helps in determining reasons for the progress of certain segments over others in the looming years. The overall market is also segmented on the basis of geography in the United States, Europe, India, Japan, China, and Southeast Asia. The geographical segmentation provides a distinct assessment of the factors supporting these regions, the favorable regulatory policies, and the impact of the political frameworks.

The global stem cell therapy market report is integrated considering the primary and secondary research methodologies that have been collected from reliable sources intended to generate a factual database. The data from market journals, publications, conferences, white papers and interviews of key market leaders are compiled to generate our segmentation and is mapped to a fair trajectory of the market during the forecast period.

Get Sample Copy of Report @

https://www.reportconsultant.com/request_sample.php?id=4868

Stem Cell Therapy market On the basis of product,

Stem Cell Therapy market On the basis on the Applications,

In This Study, The Years Considered To Estimate the Size Of stem cell therapy Market Are As Follows:

If you have any special requirements, please let us know and we will offer you the report as you want.

Read more here:
Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,...

Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora – POPSUGAR

Acne is a bummer, whether it shows up on your big day . . . or just a Monday. Chances are you've had to deal with it at some point in your life. (That's why you're reading this, right?) Whether the problem is hormonal, cystic, or something else entirely, it's pretty safe to say no one is excited when they see a new pimple in the mirror.

Now's the time to break up with breakouts for good. Here are top-rated products to add to your clear skin arsenal, straight from Sephora.

You'll find solutions to brighten and treatments to lighten (old scars), not to mention products that exfoliate skin and zap zits. There's even makeup for pimple-prone skin, too.

If you're ready to stage an acne attack (that's an attack on acne, not of acne), find the blemish-blasting products from Sephora that other shoppers are loving ahead.

Originally posted here:
Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora - POPSUGAR

The ART of Having Children – Vision Insights and New Horizons

Im looking for a sperm donor, she said.

So begins Robert Klitzmans new book. If youre imagining that Klitzman is a provocative new writer of edgy cosmopolitan fiction, guess again. In Designing Babies: How Technology Is Changing the Ways We Create Children (2020), the medical doctor explores the many ways in which babies are created today. These ARTs (assisted reproductive technologies) may seem like fiction, but theyre not. Increasing numbers of hopeful parents are investing in ART procedures.

In vitro fertilization (or IVF, the bringing together of sperm and egg outside the body) is the core ART process. Since Louise Browns birth in 1978, IVF has added more than 8 million babies to both traditional and nontraditional families. But many millions more embryos and pregnancies have been unsuccessful. The grief, frustration and financial costs can be overwhelming; even the relationship between potential parents can be ruined by the unfulfilled dream of having an ART child. Meanwhile, leftover embryos are often kept in a frozen limbo awaiting destruction, gestational adoption, or parental retrieval for another round of treatment and possible birth.

So when a friend asked Klitzman, Do you want to be the father of my child? he had plenty to think about. You wouldnt have to do anything other than donate the sperm, she assured him. He writes that although the proposition was tempting, he worried, What if I disagreed with her about how to raise our child? He eventually told her no.

I have often wondered if I made the right decision. I will never know. But the choice helped me understand the predicaments that countless potential parents confront.

We now face crucial moral, social, cultural, psychological, and existential conundrums about how to employ these technologies, he remarks; whether to monitor or control them and, if so, how; and more broadly, where as a species we are or should be heading; and what responsibilities, if any, we have in these realms.

Echoing the advice of most scientists involved in this brave new world of designing babies, he writes, We need now to enhance discussion, awareness and understandings of these issues among patients, their families, clinicians in various fields, professional organizations, policymakers, and the public at large.

Klitzman is a professor of clinical psychiatry and director of the Masters of Bioethics Program at Columbia University. He also cofounded and codirected the Center for Bioethics and is a member of the Research Ethics Advisory Panel of the US Department of Defense and of the New York State Stem Cell Commission. His previous books include, among others, The Ethics Police? (2015) and Am I My Genes? (2012).

Vision contributor Dan Cloer spoke with Klitzman about what he discovered from writing Designing Babies. The conversation began with Chinese biophysics researcher He Jiankuis reasons for proceeding with germ-line editing of human embryos.

DC He Jiankuicreated a set of guidelines called Draft Ethical Principles for Therapeutic Assisted Reproductive Technologies to support his use of CRISPR for editing human embryos last year. How would you evaluate these principles?

RK They sound good, but we need more than nice words. With ethical principles, God is in the details, so to speak. The issue with any ethical principle is how it will be interpreted and applied. And what does one do when different ethical principles conflict? In general, Hes principles are fine, but they are not complete. Most specifically, what is missing for me is that he does not address questions of risk and external review.

Its not just that there may potentially be benefits to gene editing down the line, but what are the risks for someone today? Ideally, the CRISPR gene-editing tool might be used to intervene when no alternative treatment exists and the patient will otherwise die. In this case, there are good treatments for HIV and methods for avoiding transmission of HIV to a child. Gene editing was not necessary; the risks outweighed the benefits.

Researchers and policy makers around the world struggle to lead human germ-line editing into the future.

The other crucial element in international ethical guidelines is the need for a process of external review. Its not enough for scientists to say, Im going to cure people. I made this invention in my laboratory, and Im going to give it to everyone and save their lives! There must be an outside reviewer to say, Wait a second. What is it? What are the risks? What are you going to tell people about it?

We know that every scientist has conflicts of interest. They want their discovery, intervention or innovation to work. Unfortunately, there have been many cases where scientists, in their eagerness to show that their idea works, overlook risks and problems. For instance, one of Hes principles was Organizations developing genetic cures have a deep moral obligation to serve families of every background. We know now that he had plans to develop an offshore clinic to design babies for wealthy people around the world, who would come to wherever the clinic was located. That certainly shows a conflict of interest. Was he going to provide services for poor people too? Did he feel obliged by that statement to serve everyone?

DCIVF itself is very expensivemaybe $1520,000 for one treatment cycle. Thats a high bar for many right now, even before we start adding embryo gene sequencing and, at some point, gene editing. And there is no money-back guarantee.

RKThese technologies can help us and they can hurt us. They have the potential to make us better by eliminating some diseases, but also to make us more unequal by enhancing the children of people who can pay for it.

I suspect that CRISPR will eventually be introduced at fertility clinics in various countries. Someone will come along and offer somethingIQ, physical traits, other abilitiesand it will cost thousands of dollars.

For technologies that we are using right now, like Preimplantation Genetics Diagnosis (PGD, used to examine IVF embryos for abnormalities), we already face questions of equity and access. Its great that couples who may have inherited genes associated with breast cancer can have embryos examined and screened. But the procedure is expensive and often not covered by insurance. So wealthy people can afford to screen their embryos and maybe remove a disease like breast cancer from their family. Up to now, genetic diseases have been equal-opportunity killers. In the future, I think these conditions may increasingly become diseases of the poor. Obviously a lot of social questions arise when the wealthy can remove a mutation from their gene pool while others cannot.

DCYou say that your views concerning infertility changed while writing Designing Babies. What I saw astonished me, you write. These men and women shed light on the myriad, unforeseen facets and ramifications of these new technologies and dramatically altered my views. How so?

RKI started out in some ways wary of altering the genes of future generations. But I quickly realized that there are times when it might be helpful. PGD can be used to get rid of serious diseases. The key issue is to avoid bad uses and reduce the risks. Rather than saying that designing babies will be either good or bad, the question is when is it good, and when is it bad? It is not monolithic.

DCDo you see any ethical problem in creating IVF embryos that will be tested and rejected or passed on from the clinic to the lab to be used in research? What about surrogate gestation?

RKPersonally, nobut informed consent is important. We have hundreds of thousands of unused embryos in this country. Couples understandably dont want to throw them out, but sometimes they dont want to pay for storage either. But what is the moral status of an embryo? This is also an important question in the abortion and stem-cell debates. My opinion is that if a couple is trying to avoid passing on a gene associated with a serious disease, and some embryos have that gene, then its okay not to use these embryos. These are unfortunate choices that have to be made.

Similarly, I was quite wary of the idea of buying and selling eggs or sperm, or women renting their wombs [as gestational surrogates]. There are real concerns about exploitation of women and horror stories of children abandoned when the prospective parents changed their minds and no longer wanted the child after the surrogate gave birth. But as I looked into the issue through my interviews and learned about the women who were gestational surrogates, I found that many of them were not, in fact, being exploited. They knew what they were doing: Hey, I have two or three kids of my own and if I can make $90,000 just sitting around the house, that could help me pay for my kids college education.

DCSo you began to think differently because you were no longer just at your desk mulling it over academically?

RKExactly right. I wrote this book because the public debate is still focused on whether these technologies are good or bad. Whats missing are the voices of people who are personally involved, invested. Gloria Steinem tells the story of potential exploitation and impoverished women being forced to be surrogates against their will. At least in the US, the data do not support that. Certainly exploitation is bad, and we want to avoid it. But its not clear to me that it is happening. Doing research and finding out what the lived experiences are from the people involved really opened my eyes.

This speaks to the fact that many people dont yet know much about these technologies. Its true of gene editing but also of other forms of ART: buying and selling eggs and sperm, renting wombs. It affects lots of people but goes largely unexamined because there are taboos against talking about sex and reproduction. Men dont like to talk about impotence and low sperm count, feeling it means they are not macho. Women feel great shame about the fact that their eggs arent working or that theyve had to buy someone elses eggs, and that they are therefore not genetically related to their child. Theres secrecy and fear. Parents are afraid that their daughter wont love them as much if she finds out that her mom is not actually her genetic mother. But these secrets have costs. Kids may find these things out later and can become very upset and feel betrayed. Evidence suggests that children should be told from an early age that other people helped bring them into the world, or however a parent might want to communicate that.

I also came to realize how prevalent these issues are. In Denmark, for example, 7 percent of all births occur through some form of ART, and I believe that will soon be the number in the US. This is a big issue that we need to pay more attention to, on both the personal and the policy level. The CDC [Centers for Disease Control] collect some data, but theres more to do.

DCWe dont collect and apply data very well, you say. But there are things potential users of these technologies should knowdarker things that you learned as well.

RKWe do need data, but some issues stand out even now. We know that over 40 percent of twins born through IVF have medical problems. Yet fertility doctors, using IVF, commonly implant multiple embryos to increase the odds of a successful birth; its a selling point for the clinic. If Im an IVF doctor, I can say, Look at how many live births I have. Its good marketing, but not so good for the baby. I did not know this, and many IVF patients dont know it either. Thats why many European countries that provide national health-care coverage for IVF and for neonatal intensive care units have much stricter rules than we do in the US concerning the number of embryos doctors can transfer into the womb.

A lot of data could be readily gotten, but reporting is not mandatory, and many clinics dont want to provide their statistics. Clinics that dont report are actually increasing their business, so theres almost a reverse incentive. Changes in policy could address this problem, but unfortunately the lack of data is not accidental. Many clinics dont want to tell potential customers that there may be problems; they just want to say, Well bring a baby into your life. Some clinics dont want young women they recruit as egg donors to fully understand that the procedures might cause harms, such as Ovarian Hyperstimulation Syndrome, which can have serious symptoms. Collecting and publishing more data might reveal limitations and dangers.

I would say that more information is better for those who are considering using these procedures; but some IVF doctors dont want all the data out there, and they have had sway.

DCYouve called the ART industry in the United States a kind of Wild West in terms of the relative lack of regulation. Is there a business opportunity here to form some sort of watchdog group?

RKThe American Society for Reproductive Medicine (ASRM) and other physician organizations have done a good job of coming up with guidelines in many areas, but I think they can go further. For example, ASRM permits selecting the sex of a baby for family balancing. But what does that phrase really mean? A couple has one girl and now wants a boy? Or they have four girls and now want a boy? The organization needs to be more specific. The question of enforcement also arises. In terms of egg donation, we know that young womens eggs are biologically better. But should a doctor try to get 18- to 21-year-old women to sell their eggs? How risky is this for their own reproductive future? Guidelines say doctors should not recruit such young women, but clinics often do so anyway. Hence, even when there are guidelines, many clinics dont follow them and resist stronger guidelines. Today theres little if any consequence for not adhering to them.

In this Wild West, cowboys are often doing what they want without too much supervision. There are many wonderful IVF doctors; by no means am I saying they are all bad. But oversight and greater openness to potential limitations are important.

The danger of jumping in right now and attempting to design babies using CRISPR/gene editing is that we really dont know the full effects. Patients should be able to make fully informed decisions.

DCIn the real Wild West, people knew it was wild because they had a model of what civilization looked like. But we dont have a model for reference. Were building from scratch.

RKYes. Part of this is because of ever newer technologies. But just as with implanting multiple embryos, doctors widely usedand sometimes still usetechnologies that turned out to be more harmful and less beneficial than thought. A technique called ICSI [intracytoplasmic sperm injection] took one sperm from a man with a very low sperm count and injected it directly into an egg. Now ICSI is used for two thirds of all patients, without regard to the mans fertility. But the procedure turns out to double the risk of the child having intellectual disabilities. Unfortunately many potential parents dont realize this. It may help get you pregnant, but it can cause problems.

A major challenge of the Wild West is that doctors might be making a lot of money but may not always communicate the risks as well as they should, because they have a conflict of interest: profiting from what theyre doing.

DCWhere do your books Designing Babies and Am I My Genes? overlap?

RKAt one point scientists thought they would discover the cancer gene, the alcoholic gene, the schizophrenia gene. But lo and behold, were finding out that for most common diseases and traits, many genes are involved. Diseases can also be partly genetic, partly environmental. Theres a lot of nuance.

Listing the potential causes of a disease is like describing the possible reasons for a traffic jam: Did a car break down? Was there an accident? Is a bridge closed? Is it icy? Is it rush hour? Or some combination of those?

Several companies market direct-to-consumer genetic testing, pushing the idea that these services will give you important health information and help you get control of your health. Precision medicine can indeed potentially help many people. But our genetics are complicated. Am I My Genes? explored how genetic testing serves almost as a Rorschach, with people interpreting the information in varying ways.

The idea for Designing Babies grew from my work on Genes. When I interviewed people at risk for Huntingtons, I thought I would hear about issues of discrimination or insurance. But what I heard was concerns about their kidswhether to adopt or abort, or to test embryos. I heard a very disturbing observation: If I abort or dont choose an embryo because it has the same mutation that I have, I should have been aborted; am I saying that my life was not worth living? That question still haunts me. It made me want to investigate further the ethical, moral, social and psychological questions that assisted reproductive technologies present us.

The common element and challenge that comes from both books is that we still know relatively little about genes. Its been only 60 years or so since the discovery of the DNA helix and how hereditary information is encoded. The human genome was first sequenced less than 20 years ago. Much of what we have found is not what we expected.

DNA is becoming a second language of sorts because of its most attractive promise: customized, personalized medicine.

DCYou write about individual procreative liberty. Do you have any concern that in the future parents might be pressured to use ART to avoid creating an imperfect child? Could there be a time when national health care includes or compels IVF, and that parents who opt to have children with disease will be ostracized and lose access to social services because they willingly brought a baby into the world that would require more than its share of medical and support resources?

RKPast attempts to improve the genes of people led to horrific results. Nazi Germany sought to remove bad genes by killing people. Hitler got his ideas about eugenics from the United States and our unfortunate history of racism. In the 1920s, we had eugenics fairs and better-baby contests. So we need to be very careful about efforts to improve our genes.

Given our history, however, its hard to predict what the government will do. We know that at one point the government pushed sterilization of the so-called feebleminded. And the question of abortion is obviously very contentious.

The cost of IVF will be an important factor in shaping its possible future. We dont have enough money to provide basic health services to all citizens now. So even if IVF becomes more accessible and less expensive, which I think it will to a certain degree, I dont think it will ever be mandated. People just get pregnant naturally all the time, planned or unplanned. I dont think were going to get to the point where well just not support you unless you used IVF.

DCWhat is the most important question your book helps us explore?

RKWhat kind of society do we want in terms of our ability to design babieswhether choosing or discarding certain embryos; buying and selling human eggs, sperm, and embryos; or altering genes directly?

As with all technologies, ARTs can be used for good or for bad. How do we choose the good over the bad? Do we want to live in a world where people use all of these technologies with few limits? Undoubtedly everyone in America knows someone, whether they realize it or not, who has had infertility problems and has used these technologies. These patients journeys have often been lonely and isolating.

I think the book can help open up the conversation and assist us allas individuals, as friends and family members, and as a society as a wholein figuring out how best to use these technologies for our own good.

Go here to read the rest:
The ART of Having Children - Vision Insights and New Horizons

Previous govts never thought of peoples welfare: CM – Hindustan Times

Chief minister Yogi Adityanath on Saturday said previous governments never thought about peoples welfare, while our government is continuously working on this (aspect).

He made the comment after inaugurating the new academic block of Dr Ram Manohar Lohia Institute of Medical Sciences in Lucknow.

Between 1947 and 2016, the state got 12 medical colleges. Between 2017 and 2019, 15 new medical colleges are coming up, of which seven have started admission. This is the difference in the thought process and efforts. In 70 years, 12 colleges came up. In the last three years, 15 (are being established), the chief minister said.

A proposal for 14 more medical colleges in UP had been sent to the central government, he added.

Without naming any government, the chief minister said, The central government demanded a proposal for life support ambulances but the state never sent it. When we came to power (in 2017), we got the process done in two months. At present, 250 of them (life support ambulances) have served 78,000 patients in the state. In addition, medical mobile units (MMUs) are running in 53 districts.

It is with the prime ministers vision and efforts that the state is getting two AIIMS. An effort is being made to eliminate TB by 2025 across the country, he said.

DOCTORS ASKED TO IMPROVE BEHAVIOUR

Asking doctors to improve their behaviour, Adityanath said, If you misbehave with patients, they will not come to you and your career will be finished.

Institute director Prof AK Tripathi said, We propose to start several new departments -- geriatric medicine, clinical haematology, rheumatology, hospital administration, stem cell and regenerative medicine, international medicine (climate change, tribal medicine) and plastic surgery.

Of these, geriatric medicine and clinical haematology can be started soon, Tripathi added.

The new 14-storey building inaugurated by the CM will house 240 faculty chambers, basement parking (three floors), 48 seminar rooms, four lecture theatres, each one with seats for over 200 people.

INTERNATIONAL MEDICINE DEPT LIKELY

TO ATTRACT STUDENTS

Among the new departments that have been proposed international medicine is likely to attract many students. International medicine is a field of health care, dealing with health across regional or national boundaries.

Practised very little in India, this branch will help treat international patients in a better manner, said Prof AK Tripathi.

More:
Previous govts never thought of peoples welfare: CM - Hindustan Times